NASDAQ$TMCI
Treace Medical Concepts Inc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Treace Medical Concepts Inc reported Q2 2025 revenue of $47.4 million with continued operating losses.
The company achieved 6.6% year-over-year revenue growth in the second quarter driven by higher bunion procedure kit volumes. Gross margin declined slightly to 79.7% due to product mix and inventory provisions while operating expenses decreased through sales force optimization. Net loss narrowed to $17.4 million from $21.2 million in the prior year quarter.
- Q2 revenue rose 6.6% to $47.4 million on increased procedure volumes offset by lower average selling prices.
- Gross margin was 79.7%, down from 80.2% due to distributor mix and higher inventory provisions.
- Sales and marketing expenses fell 12.2% from sales force optimization and reduced advertising spend.
- Cash and cash equivalents stood at $8.1 million with marketable securities of $61.2 million at quarter end.
Headline financials
Revenue & EPS history
Treace · Revenue · Quarterly
$47.4M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
-5.8%
Avg return
Earnings day
-5.9%
Avg return
5 days after
-3.7%
Avg return
30 days after
33%
7 / 21 earnings
Positive
+43.3%
Q3 2024
Best reaction
-62.8%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +4.7% | +31.8% | +82.3% | |
| Q4 2025 | -11.0% | -30.0% | -41.9% | |
| Q3 2025 | -28.6% | -46.6% | -56.0% | |
| Q1 2025 | -9.5% | -10.9% | -22.9% | |
| Q4 2024 | -2.1% | +0.0% | -7.4% | |
| Q3 2024 | +43.3% | +48.1% | +42.7% | |
| Q2 2024 | +2.7% | -8.5% | -13.9% | |
| Q1 2024 | -62.8% | -60.9% | -45.5% | |
| Q4 2023 | -5.7% | -6.4% | -8.9% | |
| Q3 2023 | -42.1% | -32.0% | -11.4% | |
| Q2 2023 | -16.9% | -20.3% | -31.3% | |
| Q1 2023 | -5.5% | -4.9% | -0.9% | |
| Q4 2022 | +21.1% | +19.0% | +37.5% | |
| Q3 2022 | +1.9% | +16.1% | +13.7% | |
| Q2 2022 | -1.3% | +1.0% | +10.1% | |
| Q1 2022 | -14.4% | -30.2% | -9.3% | |
| Q4 2021 | -1.0% | -7.4% | -5.7% | |
| Q3 2021 | -0.8% | -6.6% | -28.5% | |
| Q2 2021 | -3.3% | -5.9% | -3.2% | |
| Q1 2021 | +4.7% | +14.9% | +11.5% | |
| Q4 2020 | +4.7% | +14.9% | +11.5% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro